Clinical Pharmacokinetics

, Volume 48, Issue 3, pp 169–180 | Cite as

Population Pharmacokinetics and Dosing Recommendations for Cisplatin during Intraperitoneal Peroperative Administration

Development of a Limited Sampling Strategy for Toxicity Risk Assessment
  • Bernard Royer
  • Vincent Jullien
  • Emmanuel Guardiola
  • Bruno Heyd
  • Bruno Chauffert
  • Jean-Pierre Kantelip
  • Xavier Pivot
Original Research Article


Background: Ovarian cancer is the leading cause of gynaecological cancer-related death in Western countries. Intraperitoneal (IP) peroperative chemotherapy is an interesting therapeutic option. However, very few data are available regarding pharmacokinetics and especially population pharmacokinetics.

Patients and methods: Thirty-one patients with advanced epithelial cancer classified as International Federation of Gynecology and Obstetrics stage IIIC were included in the study. Blood and IP samples were taken over a 24-hour period during and after IP treatment. Both total and ultrafiltered (Uf) platinum (Pt) concentrations were analysed using a population approach with nonlinear mixed-effects modelling (NONMEM®) software. Improvement of the model with covariates was performed as well as assessment of the model using bootstrap and posterior visual predictive methods.

Results: Both IP fluid and serum pharmacokinetics were satisfactorily described with a three-compartment model for both Uf Pt and total Pt concentrations. The covariates were bodyweight for the IP volume of the total Pt model. A nomogram, based on the results of the Monte Carlo simulations, displays a dose recommendation regarding both the risk of renal toxicity and the potent efficacy of the treatment. A limited sampling strategy (LSS) allowing the estimation of potential risk of renal toxicity is also described.

Conclusion: The pharmacokinetics of cisplatin during peroperative IP chemotherapy could be successfully fitted with the present model, which allowed a dosing strategy accompanied by an LSS to facilitate the follow-up of patients.



The authors are very grateful to Dr Pauline Gerritsen-van Schieveen for her careful reading of the manuscript and her help with the English formulation. This work was supported by a grant from the Ligue contre le Cancer, Comité du Doubs. The authors have no conflicts of interest that are directly relevant to the content of this study.


  1. 1.
    Goodman MT, Howe HL. Descriptive epidemiology of ovarian cancer in the United States, 1992–1997. Cancer 2003; 97 (10Suppl.): 2615–30CrossRefGoogle Scholar
  2. 2.
    Goodman MT, Howe HL, Tung KH, et al. Incidence of ovarian cancer by race and ethnicity in the United States, 1992-1997. Cancer 2003; 97 (10Suppl.): 2676–85CrossRefGoogle Scholar
  3. 3.
    Pignata S, Pisano C, Di Maio M, et al. Medical treatment of resistant or recurrent epithelial ovarian cancer. Ann Oncol 2006; 17 Suppl. 7: vii49–50PubMedCrossRefGoogle Scholar
  4. 4.
    Bookman MA. Standard treatment in advanced ovarian cancer in 2005: the state of the art. Int J Gynecol Cancer 2005; 15 Suppl. 3: 212–20PubMedCrossRefGoogle Scholar
  5. 5.
    du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol 2005; 16 Suppl. 8: viii7–12PubMedCrossRefGoogle Scholar
  6. 6.
    Stuart GC. First-line treatment regimens and the role of consolidation therapy in advanced ovarian cancer. Gynecol Oncol 2003; 90(3 Pt 2): S8–15PubMedCrossRefGoogle Scholar
  7. 7.
    Chauffert B, Favoulet P, Polycarpe E, et al. Rationale supporting the use of vasoconstrictors for intraperitoneal chemotherapy with platinum derivatives. Surg Oncol Clin N Am 2003; 12(3): 835–48PubMedCrossRefGoogle Scholar
  8. 8.
    Markman M, Walker JL. Intraperitoneal chemotherapy of ovarian cancer: a review, with a focus on practical aspects of treatment. J Clin Oncol 2006; 24(6): 988–94PubMedCrossRefGoogle Scholar
  9. 9.
    Alberts DS, Liu PY, Hannigan EV, et al. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996; 335(26): 1950–5PubMedCrossRefGoogle Scholar
  10. 10.
    Armstrong DK, Bundy B, Wenzel L, et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354(1): 34–43PubMedCrossRefGoogle Scholar
  11. 11.
    Markman M, Bundy BN, Alberts DS, et al. Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19(4): 1001–7PubMedGoogle Scholar
  12. 12.
    Jaaback K, Johnson N. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2006; (1): CD005340Google Scholar
  13. 13.
    Fujiwara K, Armstrong D, Morgan M, et al. Principles and practice of intraperitoneal chemotherapy for ovarian cancer. Int J Gynecol Cancer 2007; 17(1): 1–20PubMedCrossRefGoogle Scholar
  14. 14.
    Quinn M, Avall-Lundqvist E, du Bois A, et al. History, scope and methodology of the 3rd International Consensus Workshop on Ovarian Cancer 2004. Ann Oncol 2005; 16 Suppl. 8: viii5–6PubMedCrossRefGoogle Scholar
  15. 15.
    Ahmad SA, Kim J, Sussman JJ, et al. Reduced morbidity following cytoreductive surgery and intraperitoneal hyperthermic chemoperfusion. Ann Surg Oncol 2004; 11(4): 387–92PubMedCrossRefGoogle Scholar
  16. 16.
    Royer B, Delroeux D, Guardiola E, et al. Improvement in intraperitoneal intraoperative cisplatin exposure based on pharmacokinetic analysis in patients with ovarian cancer. Cancer Chemother Pharmacol 2008; 61(3): 415–21PubMedCrossRefGoogle Scholar
  17. 17.
    Royer B, Guardiola E, Polycarpe E, et al. Serum and intraperitoneal pharmacokinetics of cisplatin within intraoperative intraperitoneal chemotherapy: influence of protein binding. Anticancer Drugs 2005; 16(9): 1009–16PubMedCrossRefGoogle Scholar
  18. 18.
    Elias D, Goere D, Blot F, et al. Optimization of hyperthermic intraperitoneal chemotherapy with oxaliplatin plus irinotecan at 43 degrees C after compete cytoreductive surgery: mortality and morbidity in 106 consecutive patients. Ann Surg Oncol 2007; 14(6): 1818–24PubMedCrossRefGoogle Scholar
  19. 19.
    Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 1999; 6(8): 790–96PubMedCrossRefGoogle Scholar
  20. 20.
    Kern W, Braess J, Kotschofsky M, et al. Application of cisplatin as intraoperative hyperthermic peritoneal lavage (IHPL) in patients with locally advanced gastric cancer: analysis of pharmacokinetics and of nephrotoxicity. Anticancer Res 2002; 22(5): 3099–102PubMedGoogle Scholar
  21. 21.
    Rossi CR, Foletto M, Mocellin S, et al. Hyperthermic intraoperative intraperitoneal chemotherapy with cisplatin and doxorubicin in patients who undergo cytoreductive surgery for peritoneal carcinomatosis and sarcomatosis: phase I study. Cancer 2002; 94(2): 492–9PubMedCrossRefGoogle Scholar
  22. 22.
    Tsujitani S, Fukuda K, Saito H, et al. The administration of hypotonic intraperitoneal cisplatin during operation as a treatment for the peritoneal dissemination of gastric cancer. Surgery 2002; 131(1 Suppl.): S98–104PubMedCrossRefGoogle Scholar
  23. 23.
    Markman M. New expanded, and modified use of approved antineoplastic agents in ovarian cancer. Oncologist 2007; 12(2): 186–90PubMedCrossRefGoogle Scholar
  24. 24.
    Monchaud C, Rousseau A, Leger F, et al. Limited sampling strategies using Bayesian estimation or multilinear regression for cyclosporin AUC(0–12) monitoring in cardiac transplant recipients over the first year post-transplantation. Eur J Clin Pharmacol 2003; 58(12): 813–20PubMedGoogle Scholar
  25. 25.
    Saint-Marcoux F, Marquet P, Jacqz-Aigrain E, et al. Patient characteristics influencing ciclosporin pharmacokinetics and accurate Bayesian estimation of ciclosporin exposure in heart, lung and kidney transplant patients. Clin Pharmacokinet 2006; 45(9): 905–22PubMedCrossRefGoogle Scholar
  26. 26.
    Chatelut E, Pivot X, Otto J, et al. A limited sampling strategy for determining carboplatin AUC and monitoring drug dosage. Eur J Cancer 2000; 36(2): 264–9PubMedCrossRefGoogle Scholar
  27. 27.
    Etienne MC, Leger F, Pivot X, et al. Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance. Ann Oncol 2003; 14(4): 643–7PubMedCrossRefGoogle Scholar
  28. 28.
    Beal SL, Sheiner LB, Boeckmann AJ. NONMEM users guides. Ellicott City (MD): Icon Development Solutions, 1989–2006Google Scholar
  29. 29.
    Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16(1): 31–41PubMedCrossRefGoogle Scholar
  30. 30.
    Holford N, Black P, Couch R, et al. Theophylline target concentration in severe airways obstruction: 10 or 20mg/L? A randomised concentration-controlled trial. Clin Pharmacokinet 1993; 25(6): 495–505PubMedCrossRefGoogle Scholar
  31. 31.
    Holford N, Hashimoto Y, Sheiner LB. Time and theophylline concentration help explain the recovery of peak flow following acute airways obstruction: population analysis of a randomised concentration controlled trial. Clin Pharmacokinet 1993; 25(6): 506–15PubMedCrossRefGoogle Scholar
  32. 32.
    Sheiner LB. Learning versus confirming in clinical drug development. Clin Pharmacol Ther 1997; 61(3): 275–91PubMedCrossRefGoogle Scholar
  33. 33.
    Panteix G, Beaujard A, Garbit F, et al. Population pharmacokinetics of cisplatin in patients with advanced ovarian cancer during intraperitoneal hyperthermia chemotherapy. Anticancer Res 2002; 22(2B): 1329–36PubMedGoogle Scholar
  34. 34.
    Chatelut E, Boddy AV, Peng B, et al. Population pharmacokinetics of carboplatin in children. Clin Pharmacol Ther 1996; 59(4): 436–43PubMedCrossRefGoogle Scholar
  35. 35.
    Delord JP, Umlil A, Guimbaud R, et al. Population pharmacokinetics of oxaliplatin. Cancer Chemother Pharmacol 2003; 51(2): 127–31PubMedGoogle Scholar
  36. 36.
    Urien S, Brain E, Bugat R, et al. Pharmacokinetics of platinum after oral or intravenous cisplatin: a phase 1 study in 32 adult patients. Cancer Chemother Pharmacol 2005; 55(1): 55–60PubMedCrossRefGoogle Scholar
  37. 37.
    Urien S, Lokiec F. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol 2004; 57(6): 756–63PubMedCrossRefGoogle Scholar
  38. 38.
    de Jongh FE, Gallo JM, Shen M, et al. Population pharmacokinetics of cisplatin in adult cancer patients. Cancer Chemother Pharmacol 2004; 54(2): 105–12PubMedCrossRefGoogle Scholar
  39. 39.
    Nagai N, Ogata H, Wada Y, et al. Population pharmacokinetics and pharmacodynamics of cisplatin in patients with cancer: analysis with the NONMEM program. J Clin Pharmacol 1998; 38(11): 1025–34PubMedCrossRefGoogle Scholar
  40. 40.
    de Jongh FE, Verweij J, Loos WJ, et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure. J Clin Oncol 2001; 19(17): 3733–9PubMedGoogle Scholar
  41. 41.
    Loos WJ, de Jongh FE, Sparreboom A, et al. Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values. J Clin Oncol 2006; 24(10): 1499–506PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2009

Authors and Affiliations

  • Bernard Royer
    • 1
    • 2
  • Vincent Jullien
    • 3
  • Emmanuel Guardiola
    • 4
  • Bruno Heyd
    • 5
  • Bruno Chauffert
    • 6
  • Jean-Pierre Kantelip
    • 2
  • Xavier Pivot
    • 1
    • 4
  1. 1.UMR645, INSERMBesançonFrance
  2. 2.Laboratoire de Pharmacologie CliniqueHôpital Jean Minjoz, CHU BesançonBesançonFrance
  3. 3.Groupe Hospitalier Cochin Saint-Vincent de PaulU663, INSERM, Université Paris-Descartes, Service de Pharmacologie CliniqueParisFrance
  4. 4.Service d’OncologieHôpital Jean MinjozBesançonFrance
  5. 5.Service de Chirurgie OncologiqueHôpital Jean MinjozBesançonFrance
  6. 6.Centre Régional de Lutte contre le Cancer LeclercDijonFrance

Personalised recommendations